Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

This study has been completed.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Information provided by (Responsible Party):
Roberto Bolli, University of Louisville
ClinicalTrials.gov Identifier:
NCT00474461
First received: May 15, 2007
Last updated: October 15, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.

The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.


Condition Intervention Phase
Coronary Artery Disease
Congestive Heart Failure
Biological: Intracoronary Injection (cardiac stem cell therapy)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.

Resource links provided by NLM:


Further study details as provided by University of Louisville:

Primary Outcome Measures:
  • Monitoring adverse outcomes, death, sustained/symptomatic ventricular tachycardia, infection, bleeding, MI, stroke, peripheral embolism in the hospital after drug administration, in the first month after injection, and serially afterwards. [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]

Enrollment: 33
Study Start Date: February 2009
Study Completion Date: September 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment group
Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
Biological: Intracoronary Injection (cardiac stem cell therapy)
Intracoronary injection of cardiac stem cells
No Intervention: Control group
Patients in this arm did not receive any intervention.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • LVEF < 40% (by any imaging modality: echocardiography/SPECT/LV angiography)
  • A history of Q-wave MI with a residual akinetic and nonviable scar (as evidenced by low-dose dobutamine stress echocardiogram and/or or thallium redistribution nuclear study for viability and/or an electrocardiogram)
  • Patients scheduled for surgical revascularization within few days (< 2 weeks) of the initial screening

Exclusion Criteria:

  • Age >75 by time of infusion
  • Cardiogenic shock
  • Severe co-morbidities (e.g., renal failure, liver failure)
  • Mini-CABG procedures
  • Pregnant/nursing women or women of child-bearing potential
  • Inability to provide informed consent
  • Diabetic Hgb A1c > 8.5%
  • Patients with a history of hepatitis B, hepatitis C, and HIV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00474461

Locations
United States, Kentucky
Jewish Hospital
Louisville, Kentucky, United States, 40202
Sponsors and Collaborators
University of Louisville
Brigham and Women's Hospital
Jewish Hospital and St. Mary's Healthcare
Investigators
Principal Investigator: Roberto Bolli, MD University of Louisville
  More Information

No publications provided by University of Louisville

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Roberto Bolli, Chief of the Division of Cardiovascular Medicine, University of Louisville
ClinicalTrials.gov Identifier: NCT00474461     History of Changes
Other Study ID Numbers: IOIC070833
Study First Received: May 15, 2007
Last Updated: October 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Louisville:
coronary artery disease
Heart Attack
Heart failure
Cardiac Stem Cells
Coronary Artery Bypass

Additional relevant MeSH terms:
Cardiomyopathies
Coronary Artery Disease
Coronary Disease
Heart Failure
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014